Know your compound’s 7-day repeat-dose hepatotoxicity profile.
Hurel will deliver your data within 30 days.
humanhepaticcocultureimagesheight298 ACEA Biosciences and HµREL® create the integrated, impedance-based real-time hepatic assay platform. ACEA and Hurel have joined forces to combine their technologies into a single, integrated, real-time hepatic cell-based assay platform. Both companies will offer product kits comprised of patent-pending Hurel liver models (human, canine, rat or cynomulgus monkey) pre-cultured in ACEA microtiter E-PLATES® and air-shipped to the customer, arriving ready for immediate use on ACEA’s Real-Time Cell Analyzer (“RTCA”) instrument. The formal launch of the new, integrated product is planned for the first quarter of 2015. Meanwhile, you can access the predictive insight of the new platform on a contract research basis.

Real-time repeat-dose profiling:
HµRELhumanTM primary hepatocyte co-culture models were treated with cyclophosphamide (a moderate hepatotoxicant) at concentrations ranging from 3*Cmax to 100*Cmax. Hepatotoxic response kinetics were continuously monitored over >6 days on the ACEA xCELLigence® RTCA impedance-based assay instrument. At higher concentrations, increases in hepatotoxicity were observed lagging successive dose administrations.

“ACEA’s non-invasive kinetic readouts, when combined with Hurel’s long-lasting and highly senstive hepatocyte co-cultures, will offer researchers new levels of insight into the metabolic, hepatotoxic, and cytotoxic processes they study.”
–Xiao Xu, Ph.D.
CEO, ACEA Biosciences

multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
Long-enduring infectious liver disease platform
Toxicity Ratios*
A new marker for hepatotoxic chronicity

*patent pending
a new, patent-pending
efflux transport
assay method
Superior intrinsic clearance
and biotransformation of
low-turnover drugs